---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-085197"
form_type: "8-K"
ticker: "BJDX"
cik: "0001704287"
company_name: "Bluejay Diagnostics, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T07:01:36.384235+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Bluejay Diagnostics Q3 net loss $2.29M; Toray license cut to 7.5% royalty

## Summary
- Net loss $2.29M ($2.08/share) for Q3 2023; nine-month loss $7.65M ($7.30/share).
- Cash $5.08M as of Sep 30, 2023, down from $10.1M; expects funding into Q1 2024, needs more capital.
- Renegotiated Toray license: royalty reduced from 15% to 7.5% for 10 years; 50% reduction after patent expiry.
- Plans to submit FDA 510(k) for Symphony IL-6 in first half 2024 based on August 2023 feedback.
- Also renegotiated supply agreement with Toray for cartridge component supply for clinical studies.

## SEC filing metadata
- accession: 0001213900-23-085197
- form_type: 8-K
- ticker: BJDX
- cik: 0001704287
- company_name: Bluejay Diagnostics, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1704287/000121390023085197/0001213900-23-085197-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1704287/000121390023085197/ea187862-8k_bluejay.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-085197
- JSON: https://secwatch.observer/filing/0001213900-23-085197.json
- Plain text: https://secwatch.observer/filing/0001213900-23-085197.txt

## Key facts
- Earnings Releases
  Bluejay Diagnostics, Inc. reported the three and nine months ended September 30, 2023 results: net income $2.29 million and $7.65 million, EPS $2.08 and $7.30 per share.
  - Period: the three and nine months ended September 30, 2023
  - Net income: $2.29 million and $7.65 million
  - EPS: $2.08 and $7.30 per share
  - Result: reported results
  source text: the net loss for the three and nine months ended September 30, 2023 was $2.29 million and $7.65 million, or $2.08 and $7.30 per share, respectively
  evidence_url: https://www.sec.gov/Archives/edgar/data/1704287/000121390023085197/0001213900-23-085197-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.